Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;21(1):2504243.
doi: 10.1080/21645515.2025.2504243. Epub 2025 May 14.

Interactions between interstitial lung abnormalities and immune checkpoint inhibitor therapy in non-small cell lung cancer: A review of current understanding and future directions

Affiliations
Review

Interactions between interstitial lung abnormalities and immune checkpoint inhibitor therapy in non-small cell lung cancer: A review of current understanding and future directions

Ryota Kikuchi et al. Hum Vaccin Immunother. 2025 Dec.

Abstract

Immunotherapy has revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), significantly improving survival outcomes and offering renewed hope to patients. However, the presence of interstitial lung abnormalities (ILAs) in patients with NSCLC presents unique challenges, especially due to the elevated risk of immune checkpoint inhibitor (ICI)-related pneumonitis, which can result in treatment interruptions and adversely affect prognosis. ILAs, often detected incidentally on computed tomography imaging, are associated with an increased risk of progression to interstitial lung disease and have been identified as a potential predictor of poor clinical outcomes in patients with NSCLC receiving immunotherapy. This review offers an overview of the current understanding of the interaction between ILAs and ICI therapy, discussing prevalence, radiological features, risk stratification, and management strategies. Additionally, it highlights the need for prospective, multicenter studies to establish optimal treatment modalities for patients with NSCLC having ILAs, to ensure safer and more effective immunotherapy.

Keywords: Non-small cell lung cancer; immune checkpoint inhibitors; immunotherapy; interstitial lung abnormalities; pneumonitis; prognosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Axial CT scans showing subtypes of interstitial lung abnormalities based on the presence or absence of fibrosis. (a) Non-subpleural fibrotic interstitial lung abnormalities (non-SF-ILAs). (b) Subpleural fibrotic interstitial lung abnormalities (SF-ILAs).
Figure 2.
Figure 2.
Axial CT scans showing the disappearance of ground-glass opacities due to gravity-dependent atelectasis and insufficient inspiration. (a) A chest CT scan performed with the patient in the supine position showed ground-glass opacities in the lower lobes, which disappeared (b) when the patient was placed in the prone position, proving that the ground-glass opacities were caused by gravity effects and insufficient inspiration.

References

    1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A.. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–9. doi: 10.3322/caac.21871. - DOI - PMC - PubMed
    1. National Cancer Institute . SEER cancer statistics review. Bethesda (MD): National Cancer Institute; 1975–2016. [accessed 2025 Jan 8]; https://seer.cancer.gov/archive/csr/1975_2015/index.html. p 2019.
    1. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. doi:10.1056/NEJMoa1916623. - DOI - PMC - PubMed
    1. Wei Y, Zhang R, Yin R, Wang S, Han J, Chen R, Fu Z. Immunotherapy improves the survival of stage 4 non-small cell lung cancer patients at the US population level: the real-world evidence. Clin Respir J. 2024;18(9):e70000. doi: 10.1111/crj.70000. - DOI - PMC - PubMed
    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources